Shots:

• Kite and Kiniksa enter into a clinical collaboration to conduct a P-II study assessing Yescarta + mavrilimumab in patients with r/r LBCL. Kite will sponsor and conduct the study
• The P-II study will determine the effect of GM-CSFRα inhibition with mavrilimumab on the clinical safety of Yescarta. The collaboration supports Kiniksa’s objective to develop therapies targeting unmet medical needs
• Mavrilimumab is an investigational mAb- designed to antagonize GM-CSF signaling by binding to the alpha subunit of the GM-CSF receptor while Yescarta is the first CAR T cell therapy to be approved by the US FDA to treat patients with r/r LBCL prior treated with 2L+ systemic therapy

Click here to­ read full press release/ article | Ref: Kiniksa | Image: News India times